Background-Prior work identified the fibroblast growth factor (FGF) pathway as a mediator of resistance to anti-vascular endothelial growth factor (VEGF) therapy. We tested dovitinib, an inhibitor of both FGF and VEGF receptors, in patients progressing on anti-VEGF treatment.
INTRODUCTION
Since the landmark study demonstrating a survival advantage for the addition of bevacizumab to irinotecan, 5-fluorouracil (5-FU), and leucovorin therapy for the treatment of advanced colorectal cancer (CRC) (1), several agents have been developed that target vascular endothelial growth factor (VEGF) pathway signaling. The list of approved agents now includes those that target VEGF ligands (bevacizumab, ziv-aflibercept) and the VEGF receptor 2 (ramucirumab). The approval of the multi-kinase inhibitor regorafenib, which targets VEGFR2 amongst other targets, may also be an extension of this paradigm (2) . Moreover, two of these agents have demonstrated modest improvements in treatment outcome when combined with chemotherapy in advanced non-small cell lung cancer (NSCLC) (3, 4) . Despite the promise of anti-VEGF therapy-based combinations in the treatment of advanced CRC and NSCLC, intrinsic and acquired resistance to anti-VEGF therapy results in the absence of benefit for some patients and a reduced duration of benefit for others.
The fibroblast growth factor (FGF) signaling pathway is an alternative pro-angiogenic pathway that may be an important mediator of resistance to anti-VEGF therapy (5) . FGF signaling is highly polymorphic with 22 potential ligands and 4 FGF receptor (FGFR) tyrosine kinases identified (6) . Preclinical models suggest that up-regulation of components of the FGF pathway may contribute to tumor growth and anti-angiogenic resistance. For example, in a mouse model of pancreatic islet cell tumors treated with a VEGFR-antibody, vasculature regrowth was observed 10-14 days into treatment and associated with increased mRNA expression of FGF1 and FGF2 (7) . The addition of an FGF antibody slowed revascularization in this model. Furthermore, in a phase II trial the VEGFR tyrosine kinase inhibitor cediranib (Recentin, AstraZenaca) in malignant gliomas, circulating levels of FGF2 were found to be higher in the presence of resistant tumors than in the same patients during the responsive phase (8) . While FGF pathway activation may be important for some tumors prior to any treatment, anti-VEGF therapy may select for FGF pathway activation as a resistance mechanism. Indeed, investigators studying dynamic changes in circulating angiogenic factors in patients treated with irinotecan, 5-fluorouracil (5-FU), leucovorin and bevacizumab demonstrated that FGF2 levels were strikingly elevated immediately prior to progression compared to baseline (9) . Taken together, these data suggest that the FGF pathway may be an important mediator of anti-VEGF therapy resistance. Dovitinib (TKI258, Novartis Pharmaceuticals) is an orally available investigational agent that is an inhibitor of multiple tyrosine kinases. Included in its spectrum of targets are FGFR1 (IC50 8 nM), FGFR2 (IC50 40 nM) and FGFR3 (IC50 9 nM), as well as VEGF receptors (VEGFR) 1 to 3 (10) . Potent tumor growth inhibition and anti-angiogenic activity has been observed in preclinical models of multiple tumor types (11) (12) (13) (14) . In this study, we tested the hypothesis that dovitinib would induce responses in patients whose tumors progressed within 8-weeks of an anti-VEGF strategy and explored the baseline expression of angiogenic mediators in these tumors.
PATIENTS AND METHODS

Patients
This investigator initiated study was reviewed and approved by the University of California Davis institutional review board and was performed at the University of California Davis Comprehensive Cancer Center. Written informed consent was obtained from each enrolled patient. The study was registered at clinicaltrials.gov under identifier NCT01676714.
Patients 18-years of age or older with histologically-confirmed Response Evaluation Criteria In Solid Tumors (RECIST) v1.1-measurable advanced CRC or NSCLC with < 50% squamous-cell component whose immediate prior treatment regimen included an anti-VEGF agent administered not more than 56-days from enrollment were eligible (15) . Willingness to participate in a pre-treatment research biopsy and tumor site amenable to core needle biopsy were required. Further inclusion criteria included the ability to give informed consent, Zubrod performance status 0-1, and acceptable end-organ function defined by an absolute neutrophil count > 1,500/mm3, platelet count > 100,000/mm3, hemoglobin > 9 g/dL, total bilirubin < 1.5 times the institutional upper limit of normal (ULN), ALT and AST < 3 times the ULN, and serum creatinine < 1.5 times the ULN or calculated creatinine clearance > 30 mL/min using the Cockcroft-Gault formula if the serum creatinine was 1.5 -3 times the ULN.
Exclusion criteria included ongoing side effects of prior treatment that had not resolved to grade 1 or less, known brain metastases, major surgery within 4 weeks, minor surgical procedures within 1 week, radiotherapy within 4 weeks, and prior malignancy within 3 years except for completely treated in-situ carcinoma of the uterine cervix or non-melanoma skin cancer. Further exclusion criteria included clinically significant and uncontrolled cardiac dysrhythmia, reduced left ventricular ejection fraction (LVEF) by echocardiogram or multiple gated acquisition (MUGA), systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg, and myocardial infarction, congestive heart failure, cerebrovascular ischemia, or pulmonary embolism within the prior 6 months. Pregnant or breast-feeding women were ineligible, and those biologically able to conceive were required to use highly effective barrier contraception.
Study Procedures
Prior to registration, patients underwent a history and physical examination and baseline laboratory studies, including a pregnancy test for women of child bearing potential. Assessment of LVEF by echocardiogram or MUGA was performed within 56 days of treatment, and repeated at week 12 and 24 of the study. Radiographic tumor assessment by CT or MRI was required within 4 weeks of study entry. Tumor measurements were subsequently repeated every 8 weeks. History and physical examination were performed along with assessment of hematology and chemistry profiles on day 1 and 12 of the first two 4-week cycles, then once per cycle.
At the time of enrollment, the study team including the relevant interventional radiologists selected an appropriate site for biopsy. The biopsy procedure was scheduled at least 3-weeks after the last infusion of bevacizumab or ziv-aflibercept and at least 1-week from last any anti-VEGF tyrosine kinase inhibitor. The preferred method was a core biopsy system to obtain at least 2 core biopsies not less than 20 gauge in diameter and 1 cm in length. A focused history and examination were performed after completion of the biopsy to ensure recovery from any adverse events.
Treatment Plan
Treatment began between 4 and 7 days after completion of the tumor biopsy. Dovitinib was administered with or without food at an initial dose of 500 mg for 5 days on then 2 days off continuously during 28-day cycles. Up to 2 dose reductions according to a pre-specified scale were allowed for clinically relevant toxicities, with a maximum of 14 days allowed for dose interruptions. Hormonal contraception was not allowed and barrier contraception required during the study due to potential cytochrome P450 (CYP) interactions of dovitinib and oral contraceptives. Similarly, concomitant medications with potential for interaction via CYP1A1/2, CYP2C9, and CYP2C19 were reviewed and used with caution if no alternative was available. Toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. Treatment was continued unless there was a biopsy complication until unacceptable adverse event(s), disease progression, pregnancy, the patient withdrew consent, or the investigator felt that continued treatment was no longer in the patient's best interest.
Correlative Studies
Archival tumor specimen was requested on all patients. Research tumor biopsies were formalin fixed and paraffin embedded (FFPE). Tumor samples were micro-dissected to reduce non-tumor components. RNA was isolated and gene expression was assessed using a next generation sequencing based panel with probe sequences for 2,560 genes (HTG Molecular Diagnostics, Inc.). Raw counts from the Illumina MiSeq output for each gene were filtered from background using the median negative control. Normalized expression values were then generated from expression across all samples.
Selected circulating angiogenic factors were analyzed at baseline, day 12 of cycle 1, day 1 of cycle 2, and at progression using multiplex bead based array (VEGF-A, VEGF-C, PlGF, IL-8, HGF, and soluble Tie2; R&D Luminex®) or ELISAs (FGF2, and soluble VEGFR2). Values for each patient and each time point are reported as the mean of three replicates.
Statistical Analysis
The trial was conducted using a two-stage Simon optimal design (Simon, 1989). The primary endpoint of the trial was overall response rate using RECIST 1.1 criteria. Under the assumption that a response rate of 5% or less is not worthy of further study and an Semrad et 
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alternative response rate of at least 25% or more would be of considerable interest, the initial phase was to enroll 9 evaluable patients. If 1 or more of the first 9 patients has a response, then accrual would continue until a total of 30 evaluable patients have been treated. Demographic and other baseline data were summarized descriptively. Secondary endpoints included disease control rate at 8 weeks, progression free survival (PFS), and toxicity (NCI CTCAE version 4). Gene expression values are reported as the median normalized value. Expression of circulating angiogenic factors are expressed as the mean and standard error. Given the small number of patients included and the number of tests performed, no comparative statistics were performed and the results are considered descriptive.
RESULTS
Patient Characteristics
Between March 2013 and June 2014 we enrolled ten patients with a median age of 63 years who had recently progression on anti-VEGF treatment for advanced CRC or NSCLC. The median time from administration of the last anti-VEGF treatment was 48 days and all but one patient had advanced CRC. A median of 4 prior lines of systemic treatment had been administered; the prior anti-VEGF regimen contained bevacizumab in 80% of enrolled patients and ziv-aflibercept in the remaining 20%. The study closed to new accrual in February 2015 with the termination of dovitinib development programs. Demographics of the cohort are summarized in Table 1 .
Treatment and Response
The study closed after enrolling 10 patients, three of whom were not eligible for response assessment due to withdrawal of consent for treatment and response assessment in the first cycle of therapy. The population of evaluable patients included only those with CRC, amongst whom no RECIST 1.1 response was observed in 7 evaluable patients. The overall best response was stable disease in 1 patient. The median time on treatment for the entire cohort was 40 days. For those patients who did not withdraw from therapy in cycle 1, the median time on treatment was 57 days. The median progression free survival was 1.9 months. Tumor responses for the cohort are summarized in Table 2 .
Adverse Events
There were no complications from the pre-treatment study biopsies. Treatment related toxicities were substantial; all patients had grade 3 or higher toxicities attributed to drug treatment (Table 3) . Grade 3 or higher toxicities experience by 2 or more patients included fatigue (40%), elevated GGT (40%), lymphopenia (40%), elevated alkaline phosphatase (30%), elevated aspartate aminotransferase (20%), hypoalbuminemia (20%) and generalized muscle weakness (20%). Common all grade toxicities included anorexia, nausea, hypoalbuminemia, liver function test abnormalities, generalized muscle weakness, and weight loss. There was one death after extensive bilateral pulmonary emboli that was attributed as potentially related to drug treatment.
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Molecular Correlates
Although archival tumor was requested, no samples with sufficient tissue for further analysis were available from archived specimens. All enrolled patients underwent a pre-treatment study biopsy procedure. Sufficient tumor tissue for gene expression analysis was available in 9 specimens. As one specimen was NSCLC, expression data from the CRC cohort with available specimens (n=8) is reported. Expression of multiple angiogenic mediators was common in CRC tumors progressing on anti-VEGF therapy (Figure 1 ). Prominent expression of all four FGFRs was detected, along with prominent expression of FGF ligands commonly implicated in tumor angiogenesis. Additionally high expression of VEGF pathway ligands was noted along with detectable but lower expression of VEGFR2.
Plasma FGF2 increased continuously during treatment and at progression (Figure 2) . Similarly, IL-8 values increased continuously on treatment and at progression (Supplemental Figure 1A) . The VEGF family ligands VEGF-A and placenta growth factor (PlGF) peaked in early treatment and returned to near baseline upon progression. Soluble VEGFR2 levels decreased during therapy. There was no significant change in soluble Tie2 and HGF (Supplemental Figure 1 ).
DISCUSSION
In this study, we did not confirm the activity of combined FGFR and VEGFR inhibition in tumors with resistance to anti-VEGF therapy. Dovitinib was associated with significant toxicities in this heavily pretreated patient population and although the number of treated patients was small, we observed no evidence for meaningful clinical benefit from dovitinib treatment. Nonetheless, the pre-treatment tumor biopsies that were collected shortly after progression on prior anti-VEGF therapy provide a unique opportunity to assess the expression status of angiogenic mediators in this situation.
Potential mechanisms of resistance to anti-VEGF therapy include selection for or upregulation of alternative pro-angiogenic pathways, recruitment of bone marrow derived vascular progenitors and pro-angiogenic monocytes, increased involvement of pericytes in blood vessel stability, and increased capacity for invasion without metastasis (16) (17) (18) . Based on pre-clinical and translational data, the FGF pathway has been proposed as a major alternative pro-angiogenic escape mechanism (7, 9) . In this study, we confirmed significant levels of expression of FGF ligands and receptors in tumor biopsies obtained after recent progression on treatment containing an anti-VEGF agent. We requested archival specimens from all patients on this study but sufficient tumor was not available for comparison of expression profiles prior to anti-VEGF therapy to those obtained from the study research biopsy. Nevertheless, the pattern of expression does support the potential for activation of the FGF pathway in this context. A key finding of our study is the observation of relevant levels of continued expression of VEGF pathway components as well as other proangiogenic factors. Based on these data, we speculate that the angiogenic factor milieu in tumors growing despite VEGF pathway inhibition is robust and perhaps not dependent on a single alternative angiogenic pathway.
There are a number of limitations of this study that warrant comment. Enrollment was aborted prior to completion of the first stage of the Simon 2-stage design. Nonetheless, it is unlikely that accrual of additional patients would have significantly altered the efficacy and toxicity conclusions presented. We allowed both advanced CRC and NSCLC patients to be enrolled on this study; however, enrollment was largely restricted to CRC patients. We could not confirm that dovitinib was acting as a potent FGF pathway inhibitor in this study despite preclinical and clinical data supporting potent FGF inhibition in other contexts (10, 19) . Indeed, we demonstrated that FGF pathway mediators are amongst the most expressed angiogenic mediators in patients recently progressing on anti-VEGF therapy. Thus, caution should be exercised for the extrapolation of our results to other anti-FGF strategies. Additionally, we defined anti-VEGF resistance as progression on a treatment regimen that includes an anti-VEGF agent. In the period since this study was designed, clinical data in advanced CRC demonstrated a survival advantage to the continuation of an anti-VEGF agent while changing the concomitant chemotherapy backbone (20) . This suggests that progression on an anti-VEGF therapy containing regimen is distinct from anti-VEGF therapy resistance. Moreover, the expression of VEGF pathway mediators in post-anti-VEGF therapy tumors suggests the potential for ongoing VEGF-mediated angiogenesis in these patients. Just as molecular selection of patients for anti-VEGF strategies remains an unachieved goal, the molecular and clinical definitions of resistance to anti-VEGF therapy strategies are unknown.
In conclusion, we observed significant toxicities and no meaningful activity when dovitinib was administered to a small number of CRC patients progressing on anti-VEGF therapy.
While there was evidence of VEGF pathway modulation through altered circulating angiogenic mediators, we did not confirm evidence of FGF pathway modulation. In tumors progressing despite anti-VEGF therapy, a multitude of pro-angiogenic mediators are expressed, including members of the FGF and VEGF pathways. Future studies are required to understand the interplay of multiple proangiogenic pathways active in tumors exposed to anti-VEGF therapy.
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